In the wake of the outbreak of the COVID-19, the globally cumulative infected population has capped 100 million, which poses a huge impact on human activities.
AKL Research & Development (AKLRD) and Nordic Bioscience Clinical Development, announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA).